Join Allucent experts Sugato De, MBE (VP, Regulatory Strategy, Head of MedTech) and Alex MacDonald, PhD (VP, Model Informed Drug Development) in BioPharma Dive’s new podcast. In this episode, we will delve into the innovative realm of antibody drug conjugates (ADCs) and radionuclide conjugates by exploring the tremendous growth potential of these targeted oncology therapies.
ADCs and Radionuclide Conjugate represent the future of targeted oncology treatments, offering significant growth potential and new avenues for cancer care. However, unique obstacles still present themselves for small and mid-sized biotech companies navigating this rapidly evolving field.
Our experts will share valuable insights and strategies for addressing key challenges, offering strategic advice for biotech firms striving to succeed in this competitive space. Don’t miss this opportunity to gain a deeper understanding of the transformative potential of ADCs and Radionuclide Conjugate and the critical steps required to achieve regulatory approval.
Start listening to this podcast by clicking play button below
If you’re interested in hearing about developing a strong and efficient pharmacovigilance strategy, please listen to another exciting Allucent podcast: Strategic Alliances in the Development and Execution of Pharmacovigilance Strategy.
Sugato De
VP of Regulatory Strategy and Head of Med Tech
Alex MacDonald
Vice President of model-informed drug development (MIDD)
Share This
